TARSUS PHARMACEUTICALS

Tarsus to Participate in Upcoming Investor Conferences

29 May 2024 14:00:00 By Nasdaq GlobeNewswire

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

09 May 2024 14:00:00 By Nasdaq GlobeNewswire

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

08 May 2024 13:05:01 By Nasdaq GlobeNewswire

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

01 May 2024 14:00:00 By Nasdaq GlobeNewswire

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

23 Apr 2024 05:30:00 By Nasdaq GlobeNewswire

Tarsus to Participate at Upcoming Investor Conferences

05 Mar 2024 13:30:00 By Nasdaq GlobeNewswire

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

05 Mar 2024 05:30:00 By Nasdaq GlobeNewswire

Tarsus Announces Pricing of $100.0 Million Public Offering

29 Feb 2024 21:07:38 By Nasdaq GlobeNewswire

Tarsus Announces Proposed $100.0 Million Public Offering

29 Feb 2024 13:37:35 By Nasdaq GlobeNewswire

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

27 Feb 2024 03:00:00 By Nasdaq GlobeNewswire

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

22 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

20 Feb 2024 14:00:00 By Nasdaq GlobeNewswire

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

31 Jan 2024 14:00:00 By Nasdaq GlobeNewswire

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

11 Dec 2023 05:00:00 By Nasdaq GlobeNewswire

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

09 Nov 2023 13:05:01 By Nasdaq GlobeNewswire

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

01 Nov 2023 15:35:08 By Nasdaq GlobeNewswire

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

06 Sep 2023 05:00:00 By Nasdaq GlobeNewswire

Tarsus to Present at Upcoming Investor Conferences

30 Aug 2023 13:30:00 By Nasdaq GlobeNewswire

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

24 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

10 Aug 2023 13:05:00 By Nasdaq GlobeNewswire